Updated October 25, 2026 · Sources linked below

If you are offered “peptide therapy for fat loss,” ask for the proposed treatment in writing before deciding. The phrase can refer to very different products. An informed consultation should identify exactly what is being offered and explain why it fits your medical situation.

Ask for a complete treatment description

Request the ingredient name, formulation, source, intended purpose, and monitoring plan. An FDA-approved medicine, a compounded preparation, and an investigational compound are different categories. Compounded drugs are not FDA-approved, and research labeling does not establish that a product is suitable for human use. FDA specifically states that retatrutide and cagrilintide are unapproved and cannot be used in compounding under federal law. [1]

This does not prevent discussing their research. It does mean a clinic should distinguish education about a trial from offering the investigational drug as routine care.

Look for the missing information in testimonials

A testimonial rarely tells you who did not respond, who stopped because of side effects, what other treatment was used, or how long the result lasted. Ask for the study population, comparison group, duration, and safety findings. Evidence for an approved medicine does not establish the benefit of an unrelated peptide marketed alongside it. [2]

Make follow-up concrete

A weight-management consultation should address relevant health conditions, current medicines, eating patterns, physical activity, and realistic goals. Ask who handles adverse effects, how treatment response is assessed, and what the plan is if treatment is unsuitable or unaffordable. [3]

Patient questions worth bringing

  • Can I review the written evidence before purchasing a package?
  • What established alternatives would you consider for me?
  • Which findings would lead you to change or stop treatment?
  • Does the quoted price include follow-up and necessary monitoring?

For patients in Milton, a local consultation can make follow-up easier. Location alone, however, does not establish a treatment’s quality. Clear explanations, accurate regulatory claims, and accountable clinical care are the useful standards.

Sources and further reading

  1. FDA: concerns with unapproved GLP-1 drugs, including retatrutide and cagrilintide
  2. FDA: bulk substances with potential significant safety risks, including withdrawn nominations
  3. NIDDK: choosing a safe and successful weight-loss program

Patient education from OlympusMD Wellness in Milton, Georgia. This article provides general information and does not replace an individual medical evaluation.